FWIW, below is my questions submitted to Linda, Les and Dave yesterday and Dave's reply:
"Dear Linda,
My name is Dan X. My wife and I have about xxx shares of nwbo for years. Thank you for your hardwork and this opportunity for shareholders to submit questions. Below are my questions:
1) Since the partial hold in 2015, it seems you have been afraid of promoting our own company, and why?
2) You have fiduciary duty to shareholders, in your opinion, why share price has been in this low range for years; is the share price today low, fair or high, and what is your projection in the near future in term of share price? Can you detail your reasoning in regards to the above?
3) It seems you have diverted most financial resources to build Cognate, Advent for manufacturing which seems in the end only fall into your own interest, while the underlying trial has been in constant struggle in many fronts, and as a matter of fact after 12 years, the trial still has yet to unblind. Now we are feeling once again you are diverting resources to build other manufacturing facilities without a clear sign of trial success, so that in the end you are the sole beneficiary of all this, if the trial fails. What is your opinion on the above statement?
4) Instead, why not focus on getting a successful trial done first; with that in place, financial resources should not be a problem, and then we can build manufacturing to the standard asked for by regulatory agencies, which has been actually a common practice for most small development stage biotechs? and
5) What is the status of the trial? How many patients in the trial are still alive today? When will we see data lock, unblinding and topline data?
Your reply and explanation are very much appreciated?
Dan" and
Dave Innes's reply:
"Thank you for your input. I will add these questions to the list
Stay well
Best
Dave Innes"
